Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons recall — FDA D-0103-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit